Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5376488 | 1.00 | DOT1L (0.64) | DOT1LADORA1ADORA3ADORA2ASLC29A1 | |
| SCHEMBL30898471 | 0.91 | SLC29A1 (0.71) | ADORA1ADORA3SLC29A1LMNATP53 | |
| SCHEMBL6662680 | 0.87 | ADORA1 (0.66) | DOT1LADORA1ADORA3ADORA2A | |
| SCHEMBL6662687 | 0.87 | ADORA1 (0.66) | DOT1LADORA1ADORA3ADORA2A | |
| SCHEMBL6660483 | 0.85 | ADORA3 (0.62) | ADORA1ADORA3ADORA2ARXFP1 | |
| SCHEMBL6660476 | 0.85 | ADORA3 (0.62) | ADORA1ADORA3ADORA2ARXFP1 | |
| SCHEMBL6660710 | 0.81 | SLC29A1 (0.58) | ADORA1ADORA3ADORA2ASLC29A1LMNA | |
| SCHEMBL6688139 | 0.79 | ADORA1 (0.62) | DOT1LADORA1ADORA3ADORA2ASLC29A1 | |
| SCHEMBL9815315 | 0.79 | ADORA1 (0.62) | DOT1LADORA1ADORA3ADORA2ASLC29A1 | |
| SCHEMBL9815314 | 0.79 | ADORA1 (0.62) | DOT1LADORA1ADORA3ADORA2ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1457495-A1 | Adenosine A1 receptor agonists | GLAXO GROUP LIMITED (GB) | 2004-09-15 | — | — | EP | claimed |
| US-6455510-B1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | claimed |
| EP-1030857-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | claimed |
| WO-1999024449-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | claimed |
| US-7265111-B2 | Adenosine analogues and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-04 | — | — | US | disclosed |
| EP-1527083-A1 | NOVEL ADENOSINE ANALOGUES AND THEIR USE AS PHARMACEUTICAL AGENTS | Aventis Pharma Deutschland GmbH (DE) | 2005-05-04 | — | — | EP | disclosed |
| EP-1457495-A1 | Adenosine A1 receptor agonists | GLAXO GROUP LIMITED (GB) | 2004-09-15 | — | — | EP | disclosed |
| EP-1030857-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| WO-2004003002-A1 | NOVEL ADENOSINE ANALOGUES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-08 | — | — | WO | disclosed |
| EP-1375508-A1 | N6-substituted adenosine analogues and their use as pharmaceutical agents | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-6455510-B1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| EP-1030857-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024449-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | ADORA1, ADORA2A, ADORA2B | DOT1L 4249/4885ADORA1 1/4885ADORA3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.